ArticleFoods (Basel, Switzerland)2026
Yongchun Aged Vinegar Powder: Preparation, Characterization, and Effects on Sodium Oleate-Induced Steatosis in HepG2 Cells.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hyperlipidemia is a metabolic disease of significant current concern. Research has demonstrated that hyperlipidemia is a primary risk factor for cardiovascular disease (CVD). Furthermore, hyperlipidemia significantly increases the risk of intracellular lipid peroxidation, which further contributes to the development of CVD. Dietary bioactive interventions, including polysaccharides, polyphenols, and organic acids, have demonstrated significant potential in regulating lipid metabolism and preventing chronic diseases. This study investigated the hypoglycemic effects of Yongchun aged vinegar powder (YAVP) using an in vitro model. Considering that the bioactivity of dietary components is influenced by gastrointestinal transit, YAVP was first underwent simulated gastric and intestinal digestion in vitro. The resulting digests were applied to a sodium oleate-induced high-fat HepG2 cell model. The results demonstrated that digested YAVP significantly inhibited intracellular lipid accumulation in a dose-dependent manner. Specifically, YAVP intervention substantially lowered concentrations of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), while simultaneously elevating high-density lipoprotein cholesterol (HDL-C) levels relative to the model group. These findings suggest that YAVP retains its bioactivity after simulated digestion and exerts potent hypoglycemic effects by regulating lipid profiles in HepG2 cells, supporting its potential as a functional dietary supplement for lipid management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.